Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
about
Sunitinib in the treatment of metastatic renal cell carcinomaIs there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?Immunotherapy for metastatic renal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysisRecent updates in renal cell carcinomaAdjuvant therapy for renal cell carcinoma: past, present, and futureExpression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DThe prospects of pazopanib in advanced renal cell carcinoma.Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccineRenal cell carcinoma and the use of sorafenib.Systemic adjuvant therapies in renal cell carcinomaAkt inhibitors in clinical development for the treatment of cancer.Vaccination immunotherapy--an update.Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?Choices in adjuvant therapy of melanoma.Adjuvant treatment for renal cell carcinoma.Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.Management of locally advanced renal cell carcinoma.Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.New drug therapies for advanced renal cell carcinoma.Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy.Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines.Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.Sunitinib therapy in renal cell carcinoma.Adjuvant therapy in renal cell carcinoma-past, present, and future.Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.Predicting growth of solid renal masses under active surveillance.Recent developments in the treatment of renal cell carcinoma.Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.Adjuvant and neoadjuvant therapy in renal cell carcinoma.Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.Systemic therapy for advanced renal cell carcinoma.
P2860
Q28072057-8CA07E32-8727-4738-B01F-9594EAE58CECQ28087518-08A04353-F20D-429C-872F-89998A485793Q30234458-D840FC3E-FF94-4739-9155-EDA3ACE7F64FQ30248354-56F8273E-FE84-4F88-B473-21109FB0F218Q33843677-95C5A575-E0F8-4437-9ADD-7F9E1CB6935BQ33858807-02CC5BF4-0B67-4775-9D3C-9AC5BAA09430Q34003369-4E0A2F6E-90BC-4653-BAC2-9FE055EA8CBDQ34005127-66715241-D819-432E-9038-E28608075C04Q34029148-15BB6F1C-DDA6-437C-A1F5-9E07C8175579Q34186886-0F192D84-0089-4389-9EDA-1D9BB0D482A4Q34555854-3AD8E9E5-61AC-4948-9623-5F75C78BAF47Q34656393-B1B75012-BF9E-4727-B465-764EA9CBAAFFQ34675774-D531D083-D07F-4912-B343-0FD24665D522Q35166782-0EBA5918-223C-4F32-86E7-C78817304E49Q35569322-23D1DD9A-CD1E-4FFE-A825-6F183AE2F9E1Q35628576-9868743A-0926-428E-B850-28DCF8D58659Q35851700-89A82EB3-4DA8-4833-B023-1C916F0E6CFFQ35916894-ADEBFEEA-CEBF-44E3-A68D-DFB2222753A0Q36232195-1F7C35E5-92EF-4BE5-9E53-8192816DBEE4Q36291489-4BF7F36A-DC7E-4683-B98C-0E0042E90CBEQ36301110-C922B082-A47B-4F15-B0CE-5E8B5B197014Q36429718-9DEA57B0-9D21-4617-B961-248C175FEF14Q36491239-F03E5AA5-0F22-4537-8BB7-C285C2BC6554Q36555667-A170A06D-B918-4C2D-897D-AB00EC1C0D68Q36611853-50B9FB32-31A8-49C5-A059-B535C2422614Q36691810-3A09EA2B-0F45-4977-B5CC-82BD27618831Q36995364-77F1BFE1-EAE2-43F2-8817-941EBB9B048FQ37000740-131ECED3-D270-49A6-A5A0-F1E70B0B1407Q37071204-9513264D-DE76-4FD1-BB20-2D0C2CDBBBACQ37088460-E699BBFE-62AD-42D0-A378-72A1938E03DFQ37153437-1ECDC852-00C2-42A7-9B00-5E33FF0A19E3Q37205794-E5905C38-B922-4B34-86F2-4B89529338BEQ37287106-59C3A354-E481-46B6-899D-738128E383FFQ37300942-39747E0A-F93C-427F-9CFB-45FBBEBC2740Q37414808-102BB5B2-7DC0-4643-8998-146F35619590Q37492442-68DB6C1D-13A3-4405-A32D-DD80AF74D5ADQ37508012-D7D20677-FF30-472A-A5F8-F63FC5DD3D86Q37765583-5B0294B5-1E37-4292-8B34-BA9390D8A248Q37806966-EDE952FE-BD6D-4857-AC54-9C853A6B3988Q37905583-D8692FE9-5799-45AF-A040-688652196CA1
P2860
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@ast
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@en
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@nl
type
label
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@ast
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@en
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@nl
prefLabel
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@ast
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@en
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@nl
P2093
P356
P1476
Adjuvant high-dose bolus inter ...... orking group randomized trial.
@en
P2093
Bruce G Redman
Christopher P G Tretter
David McDermott
Geoffrey R Weiss
Janice P Dutcher
Jeffrey A Sosman
John W Smith
Joseph I Clark
Kim A Margolin
Larry Flaherty
P304
P356
10.1200/JCO.2003.02.014
P407
P577
2003-06-16T00:00:00Z